Anaritide
Also known as: anaritide acetate, ANP 4-28, ANP‑1‑28, ANP(1-28), Atrial natriuretic peptide (1‑28), atrial natriuretic peptide analog, Auriculin, C‑ANP, M-1475
Source Anaritide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Anaritide is a synthetic 28‑amino‑acid analogue of atrial natriuretic peptide (ANP‑1‑28) investigated for its natriuretic and vasodilatory effects in acute heart failure and hypertension. It has never received marketing approval.
Mechanism of Action
Agonist of natriuretic peptide receptor‑A (NPR‑A) leading to increased intracellular cGMP, causing vasodilation, natriuresis and diuresis
Routes of Administration
Goals & Uses
- Inhibition of RAASNeurohormonal ModulationModerate
- Vasodilation / blood pressure reductionCardiovascularModerate
- Acute decompensated heart failureCardiovascularModerate
- Natriuresis and diuresisFluid/electrolyte ManagementModerate
- Acute heart failure managementCardiovascularLow
- Treatment of acute renal failureRenal ProtectionLow
- Hypertensive renal diseaseRenalLow
- Hypertensive crisisCardiovascularLow
- Renal sodium excretionRenalModerate
Contraindications
- Hypersensitivity to anaritide or ANP analogsImmunologicHigh
- Cardiogenic shockCardiovascularHigh
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Recent myocardial infarction (<30 days)CardiovascularModerate
- HypotensionCardiovascularHigh
- Severe hypotensionCardiovascularHigh
Adverse Effects
- Electrolyte imbalance (e.g., hyponatremia)MetabolicUncommon
- Injection site reactionsLocalUncommon
- HeadacheNeurologicCommonPain in the head or upper neck
- Electrolyte disturbancesMetabolicUncommon
- HypotensionCardiovascularCommonLow blood pressure
- FlushingVascularUncommonWarmth and redness of the skin
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- DizzinessNeurologicUncommonFeeling faint, lightheaded, or unsteady
Drug Interactions
- Loop diureticsLow
- Other vasodilators (e.g., nitroglycerin)Moderate
- ACE inhibitors or ARBsLow
- NSAIDsLowMay increase renal risk in susceptible patients
- ACE inhibitorsModerate
- AntihypertensivesModerateMay potentiate hypotensive effects in some contexts
- DiureticsModerateMay worsen dehydration or electrolyte imbalance
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patientsAgeRelative
- ElderlyAgeRelative
- Severe hypotension or hemodynamic instabilityCardiovascularAbsolute
- Renal impairment (eGFR <30 mL/min)RenalRelative
Regulatory Status
- European UnionInvestigationalNo EMA marketing authorization; limited clinical development.
- United StatesInvestigationalNever received FDA approval; studied in Phase II trials.
- United KingdomInvestigationalNot licensed; used only in research settings.
Studied in Phase I/II trials; development discontinued; not approved in any major jurisdiction.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Anaritide?
Anaritide is a synthetic 28‑amino‑acid analogue of atrial natriuretic peptide (ANP‑1‑28) investigated for its natriuretic and vasodilatory effects in acute heart failure and hypertension. It has never received marketing approval.
What is Anaritide used for?
Anaritide is educationally associated with: Inhibition of RAAS, Vasodilation / blood pressure reduction, Acute decompensated heart failure, Natriuresis and diuresis, Acute heart failure management, Treatment of acute renal failure, Hypertensive renal disease, Hypertensive crisis, Renal sodium excretion. Educational only — not medical advice.
How is Anaritide administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Anaritide?
Reported adverse effects include: Electrolyte imbalance (e.g., hyponatremia), Injection site reactions, Headache, Electrolyte disturbances, Hypotension, Flushing, Nausea, Dizziness. This list is not exhaustive — consult a qualified clinician.
Who should avoid Anaritide?
Recorded contraindications: Hypersensitivity to anaritide or ANP analogs, Cardiogenic shock, Pregnancy, Recent myocardial infarction (<30 days), Hypotension, Severe hypotension. Consult a qualified clinician before use.